HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Ningbo Tuopu Group (A/H Listing) - About the Business and Thoughts on Valuation

Pre-IPO XREAL - Thoughts on Valuation and the Outlook

Pre-IPO TOP TOY International Group - The Industry, the Business and the Valuation Outlook

Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook

Pre-IPO Banu International Holding - The Pain Points and the Outlook

Pre-IPO FS.COM - The Concerns Behind the Business Model and the Outlook

Equity Capital Markets

Frontera Therapeutics / Equity Capital Markets

<ul>
<li>Unlike gene therapy companies that heavily bet on CNS/systemic administration, Frontera's pipeline is highly concentrated in ophthalmology/cardiovascular diseases, which are the most mature and risk-controllable application areas of AAV technology.</li>
<li>Frontera has established commercial-scale production capacity for Bac/Sf9 insect cell system.This is one of the few mature paths that can reduce cost of rAAV, providing crucial flexibility for product pricing.</li>
<li>Post-Money valuation after Series B Financing was US$527 million. Under current conditions, there could be limited room for a significant premium in its IPO valuation over its Series B valuation.</li>
</ul>


Unlike gene therapy companies that heavily bet on CNS/systemic administration, Frontera's pipeline is highly concentrated in ophthalmology/cardiovascular diseases, which are the most mature and risk-controllable application areas of AAV technology.
Frontera has established commercial-scale production capacity for Bac/Sf9 insect cell system.This is one of the few mature paths that can reduce cost of rAAV, providing crucial flexibility for product pricing.
Post-Money valuation after Series B Financing was US$527 million. Under current conditions, there could be limited room for a significant premium in its IPO valuation over its Series B valuation.


Pre-IPO Frontera Therapeutics - The Promising Gene Therapy Pipeline and the Concerns Behind